Nitrobenzene

Nitrobenzene

SCHEMBL3489404

O=C(O)O.O=[N+]([O-])c1ccccc1

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Nitrobenzene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.84
LMNA P02545 2/20 0.84
CES1 P23141 3/20 0.65
CES2 O00748 2/20 0.65
TDP1 Q9NUW8 1/20 0.60
POLB P06746 2/20 0.59
MAPK1 P28482 2/20 0.59
TP53 P04637 1/20 0.57
TSHR P16473 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CRHBP P24387 1/20 0.56
ATM Q13315 1/20 0.56
CRHR2 Q13324 1/20 0.56
TLR9 Q9NR96 1/20 0.56
HPGD P15428 1/20 0.56
ALOX12 P18054 1/20 0.56
NPC1 O15118 1/20 0.55
MITF O75030 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitrobenzene SCHEMBL27075815 1.00 ALDH1A1 (0.84) ALDH1A1LMNACES1CES2TDP1
Nitrobenzene SCHEMBL2029354 1.00 ALDH1A1 (0.84) ALDH1A1LMNACES1CES2TDP1
Nitrobenzene SCHEMBL6858789 1.00 ALDH1A1 (0.84) ALDH1A1LMNACES1CES2TDP1
Nitrobenzene SCHEMBL9178806 0.97 ALDH1A1 (0.80) ALDH1A1LMNACES1CES2TDP1
Nitrobenzene SCHEMBL11825863 0.92 ALDH1A1 (0.80) ALDH1A1LMNACES1CES2TDP1
Nitrobenzene SCHEMBL27304275 0.92 ALDH1A1 (0.89) ALDH1A1LMNACES1CES2TDP1
Nitrobenzene SCHEMBL15525745 0.92 ALDH1A1 (1.00) ALDH1A1LMNACES1CES2TDP1
Nitrobenzene SCHEMBL2358164 0.92 ALDH1A1 (1.00) ALDH1A1LMNACES1CES2TDP1
Nitrobenzene SCHEMBL20411 0.92
Nitrobenzene SCHEMBL9669095 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240261221-A1 POLYOL-MODIFIED LIPID COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) 2024-08-08 US claimed
EP-4365168-A1 POLYOL-MODIFIED LIPID COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF Jenkem Technology Co., Ltd. (Tianjin) (CN) 2024-05-08 EP claimed
CN-115403761-A Polyglycol modified lipid compound and preparation method and application thereof 天津键凯科技有限公司 2022-11-29 CN claimed
WO-2022095974-A1 METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE 杭州远大生物制药有限公司 2022-05-12 WO claimed
WO-2020228618-A1 POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE 重庆派金生物科技有限公司 2020-11-19 WO claimed
CN-106977577-A The synthesis of two class abiraterone derivatives 湖南师范大学 2017-07-25 CN claimed
CN-1201055-A Beta-quinacridone pigment CIBA SC AOLDING AG (CH) 1998-12-09 CN claimed
US-12618109-B2 Orthogonal deblocking of nucleotides ILLUMINA, INC. (US) 2026-05-05 US disclosed
EP-4727690-A1 FLOW CELLS AND METHODS FOR PREPARING SURFACES THEREOF Illumina, Inc. (US) 2026-04-22 EP disclosed
EP-4426859-B1 PRIMER SETS AND METHODS AND KITS INCORPORATING THE PRIMER SETS ILLUMINA INC (US) 2026-04-15 EP disclosed
EP-4721762-A2 MODIFIED POLYAMINE POLYMERS FOR DELIVERY OF BIOMOLECULES INTO CELLS Promega Corporation (US) 2026-04-08 EP disclosed
EP-3725798-B1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2026-03-04 EP disclosed
EP-4667495-A2 BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-12-24 EP disclosed
WO-1991006678-A1 DNA SEQUENCING SRI INTERNATIONAL (US) 1991-05-16 WO disclosed
EP-0051559-B1 BASIC AND/OR CATIONIC AZO COMPOUNDS FREE FROM SULFONIC-ACID GROUPS SANDOZ AG (CH) 1984-11-07 EP disclosed
EP-0034257-B1 PROCESS FOR THE PREPARATION OF 1,4-DIAMINO-2,3-DICYANO-ANTHRAQUINONE BAYER AG (DE) 1983-01-26 EP disclosed
EP-0023645-B1 PROCESS FOR THE PREPARATION OF 1,4-DIAMINO-2,3-DICYANOANTHRAQUINONES BAYER AG (DE) 1982-07-28 EP disclosed
EP-0051559-A1 Basic and/or cationic azo compounds free from sulfonic-acid groups SANDOZ AG (CH) 1982-05-12 EP disclosed
EP-0034257-A2 Process for the preparation of 1,4-diamino-2,3-dicyano-anthraquinone BAYER AG (DE) 1981-08-26 EP disclosed
EP-0023645-A1 Process for the preparation of 1,4-diamino-2,3-dicyanoanthraquinones BAYER AG (DE) 1981-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261221-A1 POLYOL-MODIFIED LIPID COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF PLIN1, NOTUM, THEM6 ALDH1A1 3652/4885LMNA 947/4885CES1 1029/4885
US-12618109-B2 Orthogonal deblocking of nucleotides RNGTT, POLM, NSUN2 ALDH1A1 3202/4885LMNA 421/4885CES1 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.